While reporting financial results for the first quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings guidance for the full-year 2024, while maintaining annual revenue outlook.
For fiscal 2024, the company now projects adjusted earnings in a range of $2.15 to $2.35 per share, up from the prior guidance range of $2.05 and $2.25 per share.
However, the company continues to project revenues between $58.5 billion and $61.5 billion, with revenues of about $5 billion for Comirnaty, about $3 billion for Paxlovid and about $3.1 billion from legacy Seagen.
https://www.rttnews.com/3443594/pfizer-boost-fy24-adj-eps-outlook-update.aspx
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.